106 Participants Needed

AI Decision Support for Gastrointestinal Bleeding

SC
Overseen BySunny Chung, MD
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: Yale University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether participants need to stop taking their current medications.

What data supports the effectiveness of the treatment AI-CDSS, GutGPT, Machine Learning Algorithm-Based Clinical Decision Support System for gastrointestinal bleeding?

Research shows that machine learning algorithms can outperform existing clinical risk scores for gastrointestinal bleeding, helping doctors make better decisions about patient care. These algorithms can identify patients at risk and guide treatment, potentially improving outcomes.12345

Is the AI Decision Support for Gastrointestinal Bleeding safe for humans?

The research does not provide specific safety data for the AI Decision Support system itself, but it suggests that machine learning models can improve risk prediction for gastrointestinal bleeding, potentially enhancing patient care without indicating any direct safety concerns.13467

How does the AI decision support treatment for gastrointestinal bleeding differ from other treatments?

The AI decision support treatment for gastrointestinal bleeding is unique because it uses machine learning algorithms to predict patient outcomes and guide clinical decisions, unlike traditional treatments that rely on standard clinical assessments. This approach can help identify patients at different risk levels and optimize their care by using data from electronic health records to provide real-time decision support.13458

What is the purpose of this trial?

The purpose of this research study is to measure the effect on of a large language model interface on the usability, attitudes, and provider trust when using a machine learning algorithm-based clinical decision support system in the setting of bleeding from the upper gastrointestinal tract (upper GIB). Specifically, the investigators are looking to assess the optimal implementation of such machine learning algorithms in simulation scenarios to best engender trust and improve usability. Participants will be randomized to either machine learning algorithm alone or algorithm with a large language model interface and exposed to simulation cases of upper GIB.

Research Team

DS

Dennis Shung, MD

Principal Investigator

Yale School of Medicine Section of Digestive Diseases

Eligibility Criteria

This trial is for Internal Medicine and Emergency Medicine residency trainees at the study institution. It's designed to evaluate how a machine learning algorithm, with or without a large language model interface, helps in managing upper gastrointestinal bleeding.

Inclusion Criteria

Internal Medicine residency trainees at study institution
Emergency Medicine residency trainees at study institution

Exclusion Criteria

Not applicable.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Educational Module

Participants receive a baseline educational module about artificial intelligence, machine learning, and clinical decision support

1 day
1 visit (in-person)

Simulation Scenarios

Participants engage in simulation scenarios using either a machine learning algorithm alone or with a large language model interface

60 minutes
1 visit (in-person)

Follow-up

Participants are monitored for changes in attitudes towards machine learning algorithms in clinical care

Immediately after scenarios

Treatment Details

Interventions

  • Artificial Intelligent Clinical Decision Support System
Trial Overview The study tests the impact of a large language model (LLM) interface on the use of a clinical decision support system for upper gastrointestinal bleeding. Participants will be randomly assigned to use either just the algorithm or the algorithm plus LLM in simulated scenarios.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Large Language Model-based InteractionExperimental Treatment1 Intervention
LLM-powered chatbot with the machine learning dashboard to provide the risk assessment and provide rationale based on interpretability metrics provided by the dashboard in which study participants can directly interact with using natural language. Participants will be provided the Generative Pre-trained Transformer (GPT) chatbot powered machine learning model dashboard.
Group II: Machine Learning DashboardActive Control1 Intervention
Machine learning algorithm output with an interactive dashboard that can be used to explain, or interpret the input factors that contribute most towards the generated risk score. Participants will have access to the machine learning dashboard only.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials
1,963
Recruited
3,046,000+

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Trials
2,513
Recruited
4,366,000+

Findings from Research

A machine learning model developed for predicting mortality in ICU patients with acute gastrointestinal bleeding outperformed the traditional APACHE IVa risk score, achieving an area under the curve (AUC) of 0.85 compared to 0.80 for APACHE IVa.
The ML model demonstrated a higher specificity for identifying low-risk patients, with 27% specificity at 100% sensitivity, indicating it can more accurately classify patients at lower risk of mortality.
Explainable Machine Learning Model for Predicting GI Bleed Mortality in the Intensive Care Unit.Deshmukh, F., Merchant, SS.[2021]
A machine learning model developed from data of 1958 patients with upper gastrointestinal bleeding (UGIB) demonstrated superior performance in predicting the risk of hospital intervention or death within 30 days, achieving an area under the curve (AUC) of 0.91 compared to traditional scoring systems like the Glasgow-Blatchford score (AUC 0.88).
The machine learning model not only provided higher specificity at 100% sensitivity (26% vs. 12% for GBS) but also has the potential to better identify low-risk patients, allowing for safer outpatient management after emergency department visits.
Validation of a Machine Learning Model That Outperforms Clinical Risk Scoring Systems for Upper Gastrointestinal Bleeding.Shung, DL., Au, B., Taylor, RA., et al.[2021]
A machine learning model called gradient boosting (GB) was developed to predict outcomes in patients with acute lower gastrointestinal bleeding (ALGIB), using non-endoscopic data from 300 patients across two hospitals.
The GB model demonstrated superior accuracy in predicting outcomes like recurrent bleeding and severe bleeding compared to traditional logistic regression models, achieving over 88% accuracy in internal validation, which could enhance patient triage and resource allocation in emergency care.
Prediction of Outcome in Acute Lower Gastrointestinal Bleeding Using Gradient Boosting.Ayaru, L., Ypsilantis, PP., Nanapragasam, A., et al.[2023]

References

Explainable Machine Learning Model for Predicting GI Bleed Mortality in the Intensive Care Unit. [2021]
Validation of a Machine Learning Model That Outperforms Clinical Risk Scoring Systems for Upper Gastrointestinal Bleeding. [2021]
Prediction of Outcome in Acute Lower Gastrointestinal Bleeding Using Gradient Boosting. [2023]
Advancing care for acute gastrointestinal bleeding using artificial intelligence. [2021]
[Prediction and feature selection for fatal gastrointestinal bleeding recurrence in hospital via machine learning]. [2019]
Prediction of Adverse Events in Stable Non-Variceal Gastrointestinal Bleeding Using Machine Learning. [2020]
Improving the effectiveness of drug safety alerts to increase adherence to the guideline for gastrointestinal prophylaxis. [2019]
Explainable Artificial Intelligence in the Early Diagnosis of Gastrointestinal Disease. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security